Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1555065 | 0.81 | KMT2A (0.54) | ALDH1A1KMT2AMEN1LMNAGAA | |
| SCHEMBL1787541 | 0.79 | USP2 (0.69) | USP2TP53ALDH1A1KMT2AMEN1 | |
| SCHEMBL22675387 | 0.77 | USP2 (0.55) | USP2TP53ALDH1A1CYP1A2KMT2A | |
| SCHEMBL9130363 | 0.76 | USP2 (0.54) | USP2TP53ALDH1A1KMT2AMEN1 | |
| SCHEMBL1689462 | 0.75 | FOLH1 (0.54) | USP2TP53ALDH1A1KMT2AALOX15 | |
| SCHEMBL969589 | 0.75 | HPGD (0.55) | ALDH1A1KMT2AMEN1LMNAGAA | |
| SCHEMBL7811204 | 0.75 | TP53 (0.64) | USP2TP53ALDH1A1CYP1A2KMT2A | |
| SCHEMBL7663868 | 0.75 | USP2 (0.64) | USP2TP53ALDH1A1CYP1A2KMT2A | |
| SCHEMBL29351857 | 0.75 | USP2 (0.64) | USP2TP53ALDH1A1CYP1A2KMT2A | |
| Phthalic Acid SCHEMBL20659668 | 0.74 | ALDH1A1 (0.74) | ALDH1A1CYP1A2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782399-B2 | Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-10 | — | — | US | disclosed |
| US-9561201-B2 | Therapeutic compounds | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2017-02-07 | — | — | US | disclosed |
| US-20160151350-A1 | PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME | US HEALTH (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160030369-A1 | FKBP52 TARGETING AGENT PHARMACEUTICAL COMPOSITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-04 | — | — | US | disclosed |
| US-9233973-B2 | Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150011516-A1 | PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME | US HEALTH (US) | 2015-01-08 | — | — | US | disclosed |
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2014-12-04 | — | — | US | disclosed |
| US-8859207-B2 | Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-14 | — | — | US | disclosed |
| US-20120283215-A1 | PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2012-11-08 | — | — | US | disclosed |
| US-20120283215-A1 | PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2012-11-08 | — | — | US | disclosed |
| WO-2011034834-A2 | PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357628-A1 | THERAPEUTIC COMPOUNDS | NFATC1, AADAC, NAT1 | USP2 4209/4885TP53 1161/4885ALDH1A1 201/4885 |
| US-20120283215-A1 | PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME | SHBG, FKBP2, NR5A1 | USP2 1138/4885TP53 1229/4885ALDH1A1 3994/4885 |
| US-20160151350-A1 | PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME | SHBG, FKBP2, NR5A1 | USP2 1138/4885TP53 1229/4885ALDH1A1 3994/4885 |
| US-20150011516-A1 | PHARMACEUTICAL COMPOSITIONS WHICH INHIBIT FKBP52-MEDIATED REGULATION OF ANDROGEN RECEPTOR FUNCTION AND METHODS OF USING SAME | SHBG, FKBP2, NR5A1 | USP2 1138/4885TP53 1229/4885ALDH1A1 3994/4885 |
| US-20160030369-A1 | FKBP52 TARGETING AGENT PHARMACEUTICAL COMPOSITIONS | FKBP2, FKBP1A, FKBP8 | USP2 1532/4885TP53 434/4885ALDH1A1 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.